ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1168

Sex-Specific Differences in Serum Phosphate Persist in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Schatz, Martina, The University of Edinburgh Medical School, Edinburgh, Scotland, United Kingdom
  • Tavares, Rafael Cruz Santana, Universidade de Sao Paulo Faculdade de Medicina, São Paulo, SP, Brazil
  • dos Reis, Luciene, Universidade de Sao Paulo Faculdade de Medicina, São Paulo, SP, Brazil
  • Elias, Rosilene M., Universidade de Sao Paulo Faculdade de Medicina, São Paulo, SP, Brazil
  • Moyses, Rosa M.A., Universidade de Sao Paulo Faculdade de Medicina, São Paulo, SP, Brazil
Background

Phosphate (P) plays a critical role in numerous metabolic processes, and its serum levels have been linked to various clinical outcomes. Recent studies have identified sex-specific differences in serum P concentrations in the general population (GP) and propose revisiting the concept of phosphotoxicity according to sex. However, such differences have not been investigated in the context of CKD, where additional factors may have a more pronounced impact on serum P levels.

Methods

This retrospective study was conducted in an outpatient Nephrology clinic and included clinical and laboratory data from 632 patients (507 women) with CKD stages 1–5.

Results

The median age of the cohort was 51 years (IQR: 39–62), and the median serum P level was 3.5 mg/dL (IQR: 3.0–4.0). Serum P was negatively associated with age (r = –0.08; p = 0.04) and eGFR (r = –0.23; p < 0.001). Women had significantly higher serum P levels than men [3.6 mg/dL (IQR: 3.1–4.0) vs. 3.3 mg/dL (IQR: 2.9–3.9); p = 0.01]. No significant sex differences were observed in serum calcium, parathyroid hormone (PTH), 25vitamin D levels, or the use of vitamin D supplements, calcium salts, or calcitriol. In multivariate regression analysis adjusted for serum calcium, 25vitamin D, PTH, and ethnicity, serum P was independently associated with eGFR, age, and sex.

Conclusion

Our findings confirm that, even in the presence of CKD, women have higher serum P levels than men. This sex difference should be considered in the management of CKD-MBD. Furthermore, whether women with CKD experience fewer cardiovascular adverse effects from elevated P compared to men warrants further investigation.

Digital Object Identifier (DOI)